About kuros biosciences ltd. - CSBTF
Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.
CSBTF At a Glance
Kuros Biosciences Ltd.
Wagistrasse 25
Schlieren, Zurich 8952
| Phone | 41-44-733-47-47 | Revenue | 37.35M | |
| Industry | Biotechnology | Net Income | -15,275,105.16 | |
| Sector | Health Technology | 2023 Sales Growth | 98.326% | |
| Fiscal Year-end | 12 / 2024 | Employees | 5 | |
| View SEC Filings |
CSBTF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.061 |
| Price to Book Ratio | 2.263 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -20.647 |
| Enterprise Value to Sales | 3.785 |
| Total Debt to Enterprise Value | 0.046 |
CSBTF Efficiency
| Revenue/Employee | 7,469,856.919 |
| Income Per Employee | -3,055,021.032 |
| Receivables Turnover | 4.127 |
| Total Asset Turnover | 0.403 |
CSBTF Liquidity
| Current Ratio | 2.062 |
| Quick Ratio | 1.694 |
| Cash Ratio | 1.077 |
CSBTF Profitability
| Gross Margin | 82.779 |
| Operating Margin | -26.531 |
| Pretax Margin | -39.766 |
| Net Margin | -40.898 |
| Return on Assets | -16.485 |
| Return on Equity | -21.543 |
| Return on Total Capital | -20.659 |
| Return on Invested Capital | -21.028 |
CSBTF Capital Structure
| Total Debt to Total Equity | 9.73 |
| Total Debt to Total Capital | 8.867 |
| Total Debt to Total Assets | 7.27 |
| Long-Term Debt to Equity | 2.76 |
| Long-Term Debt to Total Capital | 2.515 |